Wednesday, July 6, 2022 at 7:00 PM to Wednesday, July 6, 2022 at 9:00 PM CEST

Online Event

Clinical research on psychedelics, such as psilocybin (the psychoactive ingredient in certain types of truffles and mushrooms), has experienced a renaissance in the past two decades, leading to spectacular successes in treating conditions such as addiction (1), treatment-resistant depression (2), mood (3) and anxiety disorders or even end-of-life anxiety of cancer patients (4). But what about what Michael Pollan, author of “How to change your mind” (5), calls “the betterment of well people”? Could altered states of consciousness in general and psychedelics in particular be used to support the development and personal growth of healthy individuals, and could it even be used to catalyse leadership development?

In this group event we’ll explore these questions around “altered states of consciousness” as well as the perils and promises of using those states to influence your mind, your mindset and your trajectory in life and business. Evolute Institute’s co-founders Christopher Kabakis and Dmitrij Achelrod, Ph.D., will speak to questions such as:

  • Personal development as a necessary precondition for leaders’ success in the current world
  • How altered states of consciousness induced through psychedelics and other techniques (e.g. breathwork) can facilitate personal development in healthy people
  • How psychedelics (truffles) work in the brain
  • What the pros and cons are of using psychedelics for personal growth
  • The legal status of psychedelics and how a safe and legal setting can be guaranteed
  • From the Silicon Valley to the mainstream: From “Stealing Fire” (6) to “New Work needs inner work” (7)
  • Your questions regarding inner work with altered states of consciousness

As Dr. Roland Griffiths, one of the world’s foremost psychedelic researcher from Johns Hopkins University summarized: “Meditation is the tried and true course for understanding the human mind, and psilocybin is the crash course.” – Let’s explore that idea together on July 6!

To register for the event please click here

Garcia-Romeu A, Davis AK, Erowid E, Erowid F, Griffiths RR, Johnson MW. Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic Psychedelic Use: An Online Survey. Front Psychiatry 2019; 10: 955.
Garcia-Romeu A, Griffiths RR, Johnson MW. Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Curr Drug Abuse Rev 2014; 7: 157–64.
Griffiths R, Richards W, Johnson M, McCann U, Jesse R. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol Oxf Engl 2008; 22: 621–32.
Hendricks PS. Awe: a putative mechanism underlying the effects of classic psychedelic-assisted psychotherapy. Int Rev Psychiatry Abingdon Engl 2018; 30: 331–42.
van Schalkwyk GI, Wilkinson ST, Davidson L, Silverman WK, Sanacora G. Acute psychoactive effects of intravenous ketamine during treatment of mood disorders: Analysis of the Clinician Administered Dissociative State Scale. J Affect Disord 2018; 227: 11–6.
Barrett, F.S., Doss, M.K., Sepeda, N.D. et al. Emotions and brain function are altered up to one month after a single high dose of psilocybin. Sci Rep 10, 2214 (2020).
Inverse, August 2020: Cancer patients say psilocybin can be both ‘therapy’ and ‘a beautiful experience’.
Griffiths R. R., Johnson M. W., Carducci M. A., Umbricht A., Richards W. A., Richards B. D., et al. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J. Psychopharmacol. 30 1181–1197.